Fate Therapeutics (NASDAQ:FATE – Get Rating) will release its earnings data after the market closes on Wednesday, May 3rd. Analysts expect Fate Therapeutics to post earnings of ($0.55) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link. Fate Therapeutics (NASDAQ:FATE – Get […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating)’s share price dropped 9.3% on Tuesday . The stock traded as low as $5.72 and last traded at $5.77. Approximately 679,137 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 3,473,137 shares. The stock had previously closed at $6.36. Analyst Upgrades […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) and Poseida Therapeutics (NASDAQ:PSTX – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation. Institutional and Insider Ownership 46.7% of Poseida Therapeutics shares […]
TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) and Fate Therapeutics (NASDAQ:FATE – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability. Insider & Institutional Ownership 64.8% of TCR2 Therapeutics shares […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) and TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends. Earnings & Valuation This table compares Fate Therapeutics and […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) Director Redmile Group, Llc bought 20,000 shares of the stock in a transaction that occurred on Thursday, April 20th. The shares were bought at an average price of $5.99 per share, for a total transaction of $119,800.00. Following the completion of the transaction, the director now directly owns […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) and Poseida Therapeutics (NASDAQ:PSTX – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Volatility & Risk Fate Therapeutics has a beta of […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) insider Yu-Waye Chu sold 2,532 shares of the company’s stock in a transaction dated Tuesday, April 18th. The stock was sold at an average price of $6.57, for a total value of $16,635.24. Following the completion of the transaction, the insider now owns 140,676 shares of the company’s […]
Should You Buy or Sell Fate Therapeutics Stock? Get The Latest FATE Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) Director Redmile Group, Llc bought 25,700 shares of the business’s stock in a transaction dated Friday, April 14th. The shares were bought at an average price of $6.00 per share, with a total value of $154,200.00. Following the purchase, the director now owns 12,859,119 shares in the company, […]